Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 5;13(1):59.
doi: 10.3390/pharmaceutics13010059.

Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation

Affiliations
Free PMC article

Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation

Norfatin Izzatie Mohamad Saimi et al. Pharmaceutics. .
Free PMC article

Abstract

Gemcitabine (Gem) and cisplatin (Cis) are currently being used for lung cancer treatment, but they are highly toxic in high dosages. This research aimed to develop a niosome formulation containing a low-dosage Gem and Cis (NGC), as an alternative formulation for lung cancer treatment. NGC was prepared using a very simple heating method and was further optimized by D-optimal mixture design. The optimum NGC formulation with particle size, polydispersity index (PDI), and zeta potential of 166.45 nm, 0.16, and -15.28 mV, respectively, was obtained and remained stable at 27 °C with no phase separation for up to 90 days. The aerosol output was 96.22%, which indicates its suitability as aerosolized formulation. An in vitro drug release study using the dialysis bag diffusion technique showed controlled release for both drugs up to 24 h penetration. A cytotoxicity study against normal lung (MRC5) and lung cancer (A549) cell lines was investigated. The results showed that the optimized NGC had reduced cytotoxicity effects against both MRC5 and A549 when compared with the control (Gem + Cis alone) from very toxic (IC50 < 1.56 µg/mL) to weakly toxic (IC50 280.00 µg/mL) and moderately toxic (IC50 = 46.00 µg/mL), respectively, after 72 h of treatment. These findings revealed that the optimized NGC has excellent potential and is a promising prospect in aerosolized delivery systems to treat lung cancer that warrants further investigation.

Keywords: aerosol output; cisplatin; gemcitabine; heating method; lung cancer; niosome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
3D surfaces showing the interaction effect of the surfactants (A), cholesterol (B), and glycerol solution (C) against particle size.
Figure 2
Figure 2
(a) The representative of the particle size distribution and (b) TEM images of the optimized NGC formulation at 25,000× magnification.
Figure 3
Figure 3
(a) Particle size as a function of time at different storage temperatures for 90 days. (b) Physical appearance of NGC formulation after 90 days.
Figure 4
Figure 4
UV–visible spectra of Gem, Cis, Gem–Cis, and the optimized NGC.
Figure 5
Figure 5
The cumulative release of (a) Gem and (b) Cis at different pH of SLF.

Similar articles

Cited by

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Zappa C., Mousa S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 2016;5:288–300. doi: 10.21037/tlcr.2016.06.07. - DOI - PMC - PubMed
    1. Planchard D., Besse B. Lung cancer in never-smokers. Eur. Respir. J. 2015;47:1214–1217. doi: 10.1183/09031936.00046915. - DOI - PubMed
    1. Ahmad J., Akhter S., Rizwanullah M., Amin S., Rahman M., Ahmad M.Z., Rizvi M.A., Kamal M.A., Ahmad F.J. Nanotechnology-based inhalation treatments for lung cancer: State of the art. Nanotechnol. Sci. Appl. 2015;8:55–66. doi: 10.2147/NSA.S49052. - DOI - PMC - PubMed
    1. An Q., Shi C.X., Guo H., Xie S.M., Yang Y.Y., Liu Y.N., Liu Z.H., Zhou C.Z., Niu F.J. Development and characterization of octreotide-modified curcumin plus docetaxel micelles for potential treatment of non-small cell lung cancer. Pharm. Dev. Technol. 2019;24:1164–1174. doi: 10.1080/10837450.2019.1647236. - DOI - PubMed

LinkOut - more resources